Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Publikationer 2000-2005

 

 

Publikationer från 2000-2005 sorterade efter publicerings datum.

 

2005

 

Buerger K, Ewers M, Andreasen N, Zinkowski R, Ishiguro K, Vanmechelen E, Teipel SJ, Graz C, Blennow K, Hampel H. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 2005;65:1502-1503.

 

Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. Cerebrospinal fluid amyloid b42 and tau levels correlate with AIDS dementia complex. Neurology 2005;65:1490-1492. 

 

Nilsson LK, Linderholm KR, Engberg G, Jönsson E, Paulsson L, Blennow K, Lindström LH, Nordin C, Karanti A. Persson P, Erhardt S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophrenia Res 2005;80-315-322. 

 

Westman-Brinkmalm A, Karlsson G, Brive LM, Hedberg-Fogel K, Persson R, Karlsson H, Ekman R, Blennow K. Analysis of proteins from a glioma cell line by using micro-scale solution isoelectric focusing in combination with liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005;19:3651-3658.

 

Johansson A, Zetterberg H, Hampel H, Buerger K, Prince JA, Minthon L, Wahlund LO, Blennow K. Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer’s disease. Dementia Geriatr Cogn Disord 2005;20:367-374.

 

Rüetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid-Simonsen A, McGuire J, Karlsson M, Rymo L, Davies H, Minthon L, Blennow K. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 2005;196:273-281.

 

Buerger K, Teipel S, Zinkowski R, Sunderland T, Andreasen N, Blennow K, Ewers M, DeBernardis J, Shen Y, Kerkman D, Du Y, Hampel H. Increased levels of CSF phosphorylated tau in apolipoprotein E ε4 carriers with mild cognitive impairment. Neuroscience Letters 2005; 391:48-50.

 

Iqbal K, Flory M, Khatoon S, Soininen H, Pirttila T, Lehtovirta M, Alafuzoff I, Blennow K, Andreasen N, Vanmechelen E, Grundke-Iqbal I. Subgroups of Alzheimer disease based on cerebrospinal fluid molecular markers. Ann Neurol 2005;58748-757.

 

Johansson A, Zetterberg H, Håkansson A, Nissbrandt H, Blennow K. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF tau in Alzheimer’s disease and are not associated with frontotemporal dementia or Parkinson’s disease. Neurodegenerative Dis 2005;2:28-35.

 

Zetterberg H, Nexö E, Minthon L, Boson R, Regland B, McCaddon A, Blennow K. The transcobalamin 776C>G polymorphism may be a modifiable genetic risk factor for alzheimer’s disease. Int Psychogeriatr 2005;17:329-331.

 

Höglund K, Syversen S, Lewczuk P, Wallin A, Wiltfang J, Blennow K. Statin treatment and a disease-specific peptide pattern of b-amyloid peptides in Alzheimer’s disease. Exp Brain Res 2005;164:205-214.

 

Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E. CSF amino-modified b-amyloid42 peptides and prediction of progression of mild cognitive impairment. Clin Chem 2005;51:1650-1660.

 

Anckarsäter H, Forsman A, Blennow K. Increased CSF/serum albumin ratios : a recurrent finding in violent offenders. Acta Neurol Scand 2005;112:48-50.

 

Nägga K, Garcia J, Zetterberg H, Blennow K, Gottfries J, Marcusson J. Evaluation of factors of importance for clinical dementia diagnosis. Dement Geriatr Cogn Disord 2005;19:289-298.

 

Höglund K, Tehlen KM, Syversen S, Sjögren M, von Bergmann K, Wallin A, Vanmechelen E, Vanderstichele H, Lütjohann D, Blennow K. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2005;19:256-265.

 

Blomqvist ME, Chalmers K, Andreasen N, Bogdanovic N, Wilcock GK, Cairns NJ, Feuk L, Brookes AJ, Love S, Blennow K, Kehoe PG, Prince JA. Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain. Neurobiol Aging 2005;26:795-802.

 

Zetterberg H, Hammarin AL, Nilsson P, Andersson E, Lind B, Blennow K. Nya utredningsmöjligheter vid misstänkt Creutzfeldt-Jakobs sjukdom: likvoranalys av 14-3-3 protein och T-tau/P-tau-kvot ger säkrare diagnos. Läkartidningen 2005;102:956-961.

 

Olsson A, Vanderstichele H, Andreasen N, de Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K. Simultaneous measurement of b-amyloid(1-42), tau and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336-345.

 

Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Månsson JE, Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development: increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent resistant membrane domains. J Neurochem 2005;92:171-182.

 

Zetterberg H. Increased serum concentrations of intestinal alkaline phosphatase in peritoneal dialysis. Clin Chem. 2005;51:675-6.

 

Blennow K, Popa C, Rasulzada A, Minthon L, Wallin A, Zetterberg H. There is strong evidence that professional boxing results in chronic brain damage. The more head punches during a boxer's career, the bigger is the risk. Läkartidningen. 2005;102:2468-70, 2472-5.

 

Almqvist J, Zou J, Linderson Y, Boreström C, Altiok E, Zetterberg H, Rymo L, Pettersson S, Ernberg I. Functional interaction of Oct transcription factors with the family of repeats in Epstein-Barr virus oriP. J Gen Virol. 2005;86:1261-7.

 

Bengtson P, Zetterberg H, Mellberg T, Påhlsson P, Larson G. EBV-transformed B-cells from an individual homozygously mutated (G329A) in FUT7 do not roll on E-selectin. Scand J Immunol. 2005;62:251-8

 

Zetterberg H, Zetterberg M. Evolution, exaptation and stereopsis. Arch Ophthalmol. 2005;123:1281.

 

Johansson A, Zetterberg H, Minthon L, Hampel H, Buerger K, Wahlund LO, Blennow K. Genetic Association of CDC2 with cerebrospinal fluid tau levels. Dement Geriatr Cogn Disord. 2005;20:367-74.

 

Blennow K, Johansson A, Zetterberg H. Diagnostic value of T-tau/P-tau ratio and 14-3-3b in Creutzfeldt-Jakob disease. Int J Mol Med. 2005;16:1147-9.

 

Rüetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid Simonsen A, McGuire J, Karlsson M, Davies H, Rymo L, Minthon L, Blennow K. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol. 2005;196:273-81. aEqual contribution.

 

Zetterberg H. Should the MTHFR 1298A>C polymorphism be considered in the clinical evaluation of patients at risk for thrombotic disease? Genet Med. 2005;7:655.

 

Zetterberg M, Tasa G, Prince JA, Palmér M, Juronen E, Veromann S, Teesalu P, Karlsson JO, Blennow K, Zetterberg H. Methylenetetrahydrofolate reductase genetic polymorphisms in patients with cataract. Am J Ophthalmol. 2005;140:932-4.

 

Rüetschi U, Rosen A, Karlsson G, Zetterberg H, Rymo L, Hagberg H, Jacobsson B. Proteomic analysis using protein chips to detect biomarkers in cervical and amniotic fluid in women with intra-amniotic inflammation. J Proteome Res. 2005;4:2236-42.


2004

 

Zetterberg H, Blennow K. Elevated total tau/phospho-tau ratio in autopsy-proven Creutzfeldt-Jakob disease with negative 14-3-3 test results. Neurol Sci 2004;25:301-302.

 

Paulson L, Martin P, Ljung E, Blennow K, Davidsson P. Effect on rat thalamic proteome by acute and subchronic MK-801-treatment. Eur J Pharmacol 2004;505:103-109.

 

Folkesson-Hansson S, Puchades M, Blennow K, Sjögren M, Davidsson P. Validation of a prefractionation method followed by two-dimensional electrophoresis - applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Sci 2004;2:7.

 

Strandhagen E, Zetterberg H, Aires N, Palmer M, Rymo L, Blennow K, Thelle D. The apolipoprotein E polymorphism and the cholesterol-raising effect of coffee. Lipids in Health and Disease 2004;3:26-.

 

Söderström H, Blennow K, Forsman A, Liesivouri J, Pennanen S, Tiihonen J. A controlled study of tryptophan and cortisol in violent offenders. J Neural Transm 2004;11:1605-1610.

 

Katzov H, Bennet AM, Kehoe P, Wiman B, Gatz M, Blennow K, Lenhard B, Pedersen NL, de Faire U, Prince JA. A cladistic model of ACE sequence variation with implications for myocardial infarction, Alzheimer disease and obesity. Hum Mol Genet 2004;13:2647-2657.

 

Trysberg E, Blennow K, Zachrisson O, Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 2004;6:551-556.

 

Strandhagen E, Zetterberg H, Aires N, Palmer M, Rymo L, Blennow K, Landaas S, Thelle DS. The methylenetetrahydrofolate reductase C677T polymorphism is a major determinant of coffee-induced increase of plasma homocysteine: A randomized placebo controlled study. Int J Mol Med 2004;13:811-815.

 

Zetterberg H, Andreasen N, Blennow K. Increased cerebrospinal fluid levels of transforming growth factor-b1 in Alzheimer’s disease. Neurosci Lett 2004;367:194-196.

 

Sjögren M, Folkesson S, Blennow K, Tarkowski E. Increased inflammatory activity in frontotemporal dementia – pathophysiologicla implications. J Neurol Neurosurg Psychiatry 2004;75:1107-1111.

 

Gottfries J, Sjögren M, Holmberg B, Rosengren L, Davidsson P, Blennow K. Proteomics for drug target discovery. Chemom Intel Lab Syst 2004;73:47-53.

 

Schmitt A, Wilczek K, Blennow K, Maras A, Jatzko A, Petroianu G, Braus DF, Gattaz WF. Altered thalamic membrane phospholipids in schizophrenia: a post-mortem study. Biol Psychiatry 2004;56:41-45.

 

Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE epsilon4 Allele is Associated with Reduced Cerebrospinal Fluid Levels of Abeta42. Neurology 2004;62:2116-2118.

 

Olsson A, Csajbok L, Öst M, Höglund K, Nylén K, Rosengren L, Nellgård B, Blennow K. Marked increase of b-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury. J Neurol 2004:251:870-876.

 

Zetterberg M, Zetterberg H, Tasa G, Palmér M, Juronen E, Veromann S, Teesalu P, Gustafsson K, Rymo L, Karlsson JO, Blennow K. Apolipoprotein E polymorphism in patients with cataract. Br J Ophtalmology 2004;88:716-718.

 

Regland B, Abrahamsson L, Blennow K, Grenfeldt B, Gottfries CG CSF-methionine is elevated in psychotic patients. J Neural Transm 2004;111:631-640.

 

Blomqvist M, Silburn PA, Duchanan DD, Andreasen N, Blennow K, Pedersen NL, Brookes AJ, Mellick GD, Prince JA. Sequence variation in the proximity of IDE may Impact Age at Onset of both Parkinson’s Disease and Alzheimer’s Disease. Neurogenetics 2004;5:115-119.

 

Ryberg H, Söderling AS, Davidsson P, Blennow K, Caidahl K, Persson LI. Cerebrospinal fluid levels of free 3-nitrotyrosine are not elevated in the majority of patients with amyotrophic lateral sclerosis or Alzheimer’s disease. Neurochem Int 2004;45:57-62.

 

Johansson A, Katzov H, Zetterberg H, Feuk L, Johansson B, Bogdanovic N, Andreasen N, Lenhard B, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Variants of CYP46A1 interact with age and APOE to influence CSF Ab42 levels in Alzheimer’s disease. Hum Genet 2004;114:581-587.

 

Kehoe PG, Katzov H, Andreasen N, Gatz M, Wilcock GK, Cairns NJ, Palmgren J, de Faire U, Brookes AJ, Pedersen NL, Blennow K, Prince JA. Common variants of ACE contribute to variable age-at-onset of Alzheimer’s disease. Hum Genet 2004;114:478-483.

 

Blomqvist MEL, Andreasen N, Bogdanovic N, Blennow K, Brookes AJ, Prince JA. Genetic Variation in CTNNA3 encoding Alpha-3 catenin and Alzheimer’s Disease. Neurosci Lett 2004;358:220-222.

 

Katzov H, Chalmers K, Palmgren J, Andreasen N, Johansson B, Cairns NJ, Gatz M, Wilcock GK, Love S, Pedersen NL, Brookes AJ, Blennow K, Kehoe PG and Prince JA. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative trait related to b-amyloid metabolism. Hum Mutat 2004;23:358-367.

 

Höglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K. Plasma levels of b-amyloid(1-40), b-amyloid(1-42) and total b-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 2004:61:333-337.

 

Paulson L, Martin P, Nilsson CL, Ljung E, Westman-Brinkmalm A, Blennow K, Davidsson P. Comparative proteome analysis of thalamus in MK-801 treated rats. Proteomics 2004;4:819-825.

 

Diamandis EP, Scorilas A, Kishi T, Blennow K, Luo LY, Soosaipillai A, Rademaker AW, Sjögren M. Altered kallikrein 7 and 10 concentration in cerebrospinal fluid of patients with Alzheimer's Disease and frontotemporal dementia. Clin Biochem 2004;37:230-237.

 

McCaddon A, Blennow K, Hudson P, Hughes A, Barber J, Gray R, Davies G, Williams JHH, Duguid J, Lloyd A, Tandy S, Everall M, Cattell H, McCaddon A, Ellis D, Palmér M, Bogdanovic N, Gottfries CG, Zetterberg H, Rymo L, Regland B. Transcobalamin polymorphism and serum holo-transcobalamine in relation to Alzheimer’s disease. Dement Geriatr Cogn Disord 2004:17:215-221.

 

Trysberg E, Höglund K, Svenungsson E, Blennow K, Tarkowski A. Decreased levels of soluble amyloid b-protein precursor and b-amyloid protein in cerebrospinal fluid pf patients with systemic lupus erythematosus. Arthritis Res Ther 2004:6:129-136.

 

Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K. Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease: A Comparative Cerebrospinal Fluid Study. Arch Gen Psychiatry 2004;61:95-102.

 

Dahl A, Eriksson P S, Davidsson P, Persson A I, Ekman R, and Westman-Brinkmalm A.

Demonstration of multiple novel glycoforms of the stem cell survival factor CCg

Journal of neuroscience research, 77(1) (2004) 9

 

Zetterberg H. Methylenetetrahydrofolate reductase and transcobalamin genetic polymorphisms in human spontaneous abortion: biological and clinical implications. Reprod Biol Endocrinol. 2004;17:7.

 

McCaddon A, Blennow K, Hudson P, Hughes A, Barber J, Gray R, Davies G, Williams JH, Duguid J, Lloyd A, Tandy S, Everall M, Cattell H, McCaddon A, Ellis D, Palmer M, Bogdanovic N, Gottfries CG, Zetterberg H, Rymo L, Regland B. Transcobalamin polymorphism and serum holo-transcobalamin in relation to Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;17:215-21.

 

Zetterberg H, Blennow K. Cerebrospinal fluid markers for early and accurate diagnosis of Alzheimer's disease. Neurodégénérescence et vieillissement cerebral. Eds BF Michel & JM Verdier. Solal. 2004.

 

Zetterberg M, Zetterberg H, Palmer M, Rymo L, Blennow K, Tasa G, Juronen E, Veromann S, Teesalu P, Karlsson JO, Hoglund K. Apolipoprotein E polymorphism in patients with cataract. Br J Ophthalmol. 2004;88:716-8.

 

Zetterberg H, Boreström C, Nilsson T, Rymo L. Multiple EBNA1-binding sites within oriPI are required for EBNA1-dependent transactivation of the Epstein-Barr virus C promoter. Int J Oncol. 2004;25:693-6.

 

Zetterberg H, Nilsson-Ehle H. False-negative result in the detection of an IgM monoclonal protein by capillary zone electrophoresis. Clin Chem. 2004;50:1878-80.


2003

 

Tisell M, Tullberg M, Månsson JE, Fredman P, Blennow K, Wikkelsø C. Differences in cerebrospinal fluid dynamics do not affect the levels of biochemical markers in ventricular CSF from patients with aqueductal stenosis and Idiopathic normal pressure hydrocephalus. Eur J Neurology 2003, accepted.

 

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel D, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K. Value of CSF ß-Amyloid1-42 and tau as predictors of Alzheimer’s disease in patients with mild cognitive impairment. Molecular Psychiatry 2003;0:1-6.

 

Yhede R, Blennow K, Forsman A, Söderström H. The activity in the CNS catecholaminergic systems covaries with thyroid hormone metabolism in humans. J Neural Transm 2003;110:1369-1373.

 

Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer’s disease. Neurosci Lett 2003;352:67-69.

 

Puchades M, Folkesson Hansson S, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer’s disease. Mol Brain Res 2003;118:140-146.

 

Johansson A, Larsson A, Nygren I, Blennow K, Askmark H. Increased serum and cerebrospinal fluid FGF-2 levels in amyotrophic lateral sclerosis. NeuroReport 2003;14:1867-1869.

 

Wallin A, Sjögren M, Davidsson P. Blennow K. Decreased cerebrospinal fluid acetylcholinesterase in patients with subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord 2003;16:200-207.

 

Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, Blennow K, Brookes AJ. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat 2003;22:363-371.

 

Olsson A, Hoglund K, Sjogren M, Andreasen N, Minthon L, Lannfelt L, Buerger K, Moller HJ, Hampel H, Davidsson P, Blennow K. Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 2003;183:74-80.

 

Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation preceeds sevelopment of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003;74:1200-1205.

 

Zetterberg H, Zafiropoulos A, Spandidos DA, Rymo L, Blennow K. Gene-gene interaction between fetal MTHFR 677C>T and transcobalamin 776C>G polymorphisms in human spontaneous abortion. Hum Reprod 2003;18:1948-1950.

 

Olsson A, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Unaltered plasma levels of b-amyloid(1-40) and b-amyloid(1-42)upon stimulation of human platelets. Dement Geriatr Cogn Disord 2003;16:93-97.

 

Zetterberg H, Coppola A, D’Angelo A, Palmér M, Rymo L, Blennow K. No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. Thromb Res 2003;108:127-131.

 

Lehmann W, Regland B, Blennow K, Gottfries CG. Vitamin B12-B6-folate treatment improves blood-brain barrier function in patients with hyperhomocysteinemia and cognitive impairment. Dement Geriatr Cogn Disord 2003;16:145-150.

 

Zetterberg H, Palmér M, Boreström C, Rymo L, Blennow K. The transcobalamin codon 259 polymorphism should be designated 776C>G, not 775G>C. Blood 2003;101:3749-3750.

 

Johansson A, Hampel H, Faltraco F, Buerger K, Minthon L, Bogdanovic N, Sjögren M, Zetterberg H, Forsell L, Lilius L, Wahlund LO, Rymo L, Prince JA, Blennow K. Increased frequency of a new polymorphism in cell division cycle 2 (cdc2) gene in patients with Alzheimer ‘s disease and frontotemproal dementia. Neurosci Lett 2003;340:69-73.

 

Zetterberg H, Nexö E, Regland B, Minthon L, Boson R, Palmér M, Rymo L, Blennow K. The transcobalamin (TC) codon 259 genetic polymorphism influences holo-TC concentration in cerebrospinal fluid from patients with Alzheimer disease. Clin Chem 2003;49:1195-1198.

 

Kehoe PG, Katzov H, Feuk L, Bennet AM, Johansson B, Wiman B, de Faire U, Cairnes NJ, Wilcock GK, Brookes AJ, Blennow K and Prince JA. Haplotypes Extending Across ACE are associated with Alzheimer's Disease. Human Mol Genet 2003;12:859-867.

 

Sun YX, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S. Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer’s disease. Dementia Geriatr Cogn Disord 2003;16:136:144.

 

Sáez-Valero J, Fodero LR, Sjögren M, Andreasen N, Amici S, Gallai V, Vanderstichele H, Vanmechelen E, Parnetti L, Blennow K, Small DH. Glycosylation of acetylcholinesterase and butyrylcholinesterase changes as a function of the duration of Alzheimer’s disease. J Neurosci Res 2003;72:520-526.

 

Zhukareva V Sundarraj S, Mann D, Sjögren M, Blennow K, Clark CM, McKeel DW, Goate A, Lippa CF, Vonsattel JP, Growdon JH, Trojanowski JQ, Lee VMY. Selective reduction of soluble tau proteins in sporadic and familial frontotemporal dementia: an international follow-up study. Acta Neuropathol 2003;105:469-476.

 

Sjögren M, Gustafsson K, Syversen S, Olsson A, Edman Å, Davidsson P, Wallin A, Blennow K. Treatment with simvastatin in patients with Alzheimer’s disease lowers both a- and b-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003;16:25-30.

 

Stefanova E, Blennow K, Almkvist O, Hellström-Lindahl E, Nordberg A. Cerebral glucose metabolism, cerebrospinal fluid-b-amyloid1-42 (CSF-Ab42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 2003;338:159-163.

 

Hamberger A, Huang YL, Zhu H, Bao F, Ding M, Blennow K, Olsson A, Hansson HA, Viano D, Haglid KG. Redistrubution of neurofilaments and accumulation of b-amyloid protein after brain injury by rotational accelerati0on of the head. J Neurotrauma 2003;20:169-178.

 

Strozyk D, Blennow K, White LR, Launer LJ. CSF Ab42 levels correlate with amyloid-neuropathology in a polpulation-based autopsy study. Neurology 2003;60:652-656.

 

Paulson L, Martin P, Persson A, Nilsson CL, Ljung E, Westman-Brinkmalm A, Eriksson PS, Blennow K, Davidsson P. Comparative genome- and proteome analysis of cerebral cortex from MK-801 treated rats. J Neurosci Res 2003;71:526-533.

 

Sáez-Valero J, Costell M, Sjögren M, Andreasen N, Blennow K, Luque JM. Altered levels of cerebrospinal fluid reelin in frontotemporal dementia and Alzheimer’s disease. J Neurosci Res 2003;72:132-136.

 

Söderström H, Blennow K, Forsman A. New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathy traits. J Neurol Neurosurg Psychiatry 2003;74:918-921.

 

Wahlund LO, Blennow K. Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients. Neurosci Lett 2003;339:99-102.

 

Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163:1524-1528.

 

Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and Ab42 predicts development of Alzheimer’s disease in patients with mild cognitive impairment. Acta Neurol Scand 2003;107(Supp 179):47-51.

 

Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta—amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dem Geriatr Cogn Disord 2003;15:169-176.

 

Holmberg B, Johnels B, Blennow K, Rosengren L. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson’s disease and progressive supranuclear palsy. Mov Disord 2003;18:186-190.

 

Dahl A, Eriksson PS, Persson AI, Karlsson G, Davidsson P, Ekman R, and Westman-Brinkmalm A. Identification of proteins in conditioned medium from cultured adult hippocampal progenitor cells.

Rapid Communications in Mass Spectrometry, 17(19) (2003) 2195-202

 

Davidsson P, Westman-Brinkmalm A, Karlsson G, Persson R, Lindbjer M, Puchades M, Folkesson S, Paulson L, Dahl A, Rymo L, Silberring J, Ekman R and Blennow K. Clinical mass spectrometry in neuroscience. Proteomics and peptidomics. Cellular and Molecular Biology, 49(5) (2003) 681

 

Ribom D, Westman-Brinkmalm A, Smits A and Davidsson P. Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas.Tumour Biology 24(2) (2003) 94

 

Boreström C, Zetterberg H, Liff K, Rymo L. Functional interaction of nuclear factor Y and Sp1 is required for activation of the Epstein-Barr virus C promoter. J Virol. 2003;77:821-9.

 

Johansson A, Hampel H, Faltraco F, Buerger K, Minthon L, Bogdanovic N, Sjögren M, Zetterberg H, Forsell L, Lilius L, Wahlund LO, Rymo L, Prince JA, Blennow K. Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer's disease and frontotemporal dementia. Neurosci Lett. 2003;340:69-73.


2002

 

Feuk L, Prince JA, Blennow K, Brookes AJ. Further evidence for role of a pomoter variant in the TNFRSF6 gene in Alzheimer’s disease. Hum Mutat 2002;21:53-60.

 

Zetterberg H, Rymo L, Coppola A, D'Angelo A, Spandidos DA, Blennow K. Reply to 'MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis'. Eur J Hum Genet. 2002;10:579-582.

 

Zetterberg H, Regland B, Palmér M, Rymo L, Zafiropoulos A, Arvanitis DA, Spandidos DA, Blennow K. The transcobalamin codon 259 polymorphism influences the risk of human spontaneous abortion. Human Reproduction 2002;17:3033-3036.

 

Zetterberg H, Regland B, Palmer M, Ricksten A, Palmqvist L, Rymo L, Arvanitis DA, Spandidos DA, Blennow K. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet. 2002;10:113-8.

 

Zetterberg H, Regland B, Palmer M, Ricksten A, Palmqvist L, Rymo L, Arvanitis DA, Spandidos DA, Blennow K. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genetics 2002;10:113-118.

 

Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L, Andreasen N, Sjögren M, Blennow K. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. NeuroReport 2002;13:611-615.

 

Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptok U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Moeller HJ, Davies P, Hampel H. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002;59:627-629.

 

Nägga K, Gottfries J, Blennow K, Marcusson J. Cerebroispinal fluid phospho-tau, total tau, b-amyloid1-42 in the differentiation between Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord 2002;14:183-190.

 

Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McColloch C, Kohnken R, Padberg F, Pirttila T, Schapiro MB, Rapoport SI, Möller HJ, Davies P, Hampel H. Differential diagnsis of Alzheimer’s disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol 2002;59:1267-1272.

 

Zetterberg H, Palmér M, Ricksten A, Poirier J, Palmqvist L, Rymo L, Zafiropoulos A, Arvanitis DA, Spandidos DA, Blennow K. Influence of the apolipoprotein E e4 allele on human embryonic development. Neurosci Lett 2002;324:189-192.

 

Berggren U, Eriksson M, Fahlke C, Blennow K, Sundkler A, Balldin J. Platelet monoamine oxidase-B activity in type I alcohol-dependent subjects in sustained full remission. Alcohol and Alcoholism 2002;37:340-343.

 

Davidsson P, Sjögren M, Andreasen N, Lindbjer M, Nilsson CL, Westman-Brinkmalm A, Blennow K. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res. 2002;109:128-133.

 

Eriksson M, Berggren U, Fahlke C, Blennow K, Balldin J. Platelet monoamine oxidase B in family history positive and family history negative type 1 alcohol-dependent subjects. Alcohol Alcohol 2002,37:577-580.

 

Sjögren M, Wikkelsö C, Östling S, Wallin A, Blennow K. Biological correlates of clinical subgroups of Alzheimer’s disease. Dement Geriatr Cogn Disord 2002;14:191-197.

 

Davidsson P, Folkesson S, Christiansson M, Lindbjer M, Dellheden B, Blennow K, Westman-Brinkmalm A. Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom 2002;16:2083-2088.

 

Sjögren M, Davidsson P, Wallin A, Granérus AK, Grundström E, Askmark H, Vanmechelen E, Blennow K. Decreased CSF b-amyloid42 in Alzheimer’s disease and amyotrophic lateral sclerosis may reflect mismetabolism of b-amyloid induced by separate mechanisms. Dementia Geraitr Cogn Disord 2002;13:112-118.

 

Tarkowski E, Issa R, Sjögren M, Wallin A, Blennow K, Tarkowski A, Kumar P. Increased intrathecal levels of the angiogenetic factors VEGF and TGF-b in Alzheimer’s disease and vascular dementia. Neurobiol Aging 2002;23:237-243.

 

Sundman-Eriksson I, Blennow K, Davidsson P, Dandenell AK, Marcusson J. Increased [3H]Tiagabine Binding to GAT-1 in the Cingulate Cortex in Schizophrenia. Neuropsychobiology 2002;45:7-11.

 

Landén M, Davidsson P, Gottfries CG, Månsson JE, Blennow K. Reduction of the synaptophysin level but normal levels of glycerophospholipids in the gyrus cinguli in schizophrenia. Schizophrenia Res 2002;55:83-88.

 

Mathé AA, Ågren H, Wallin A, Blennow K. Calcitonin gene-related peptide and calcitonin in CSF of patients with dementia and depression: possible disease markers. Prog Neuro-Psychopharmacol and Biol Psychiat 2002;26:41-48.

 

Bogdanovic N, Davidsson P, Gottfries J, Volkman I, Winblad B, Blennow K. Regional and cellular distribution of synaptic proteins in the normal human brain. Brain Aging 2002;2:18-30.

 

Westman-Brinkmalm A and Davidsson P. Comparison of preparative and analytical 2-D electrophoresis for isolation and MALDI-TOF analysis of transthyretin in cerebrospinal fluid

Analytical Biochemistry, 301(2) (2002) 161

 

Westman-Brinkmalm A and Brinkmalm G. ”Mass Spectrometry Instrumentation” a chapter in the book ”Mass Spectrometry - a Challenge in Neuropeptide Research, Application in Bioscience”, edited by Jerzy Silberring and Rolf Ekman, Publisher: John Wiley & sons (April 2002)

 

Ekman R, Persson R, Nilsson CL. Neurodevelopmental influences on the immune system reflecting brain pathology. Neurotox Res. 2002 Aug; 4(5-6):565-72.

 

Zetterberg H, Jansson A, Rymo L, Chen F, Karlsson A, Klein G, Brodin B. The Epstein-Barr virus ZEBRA protein activates transcription from the early lytic F promoter by binding to a promoter-proximal AP-1-like site. J Gen Virol. 2002;83:2007-14.

 

Zetterberg H, Coppola A, D'Angelo A, Palmer M, Rymo L, Blennow K. No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyperhomocysteinemia in thrombotic disease. Thromb Res. 2002;108:127-31.


2001

 

McCaddon A, Blennow K, Hudson P, Regland B, Hill D. Transcobalamine polymorphism and homocysteine. Blood 2001;98:3497-3498.

 

Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001;313:96-98.

 

Sjögren M, Gisslén M, Vanmechelen E, Blennow K. Low cerebrosinal fluid b-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci Lett 2001;314:33-36.

 

Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Differential increase in cerebrospinal fluid-acetylcholine esterase after treatment with acetylcholine esterase inhibitors in patients with Alzheimer’s disease. Neurosci Lett 2001;300:157-160.

 

Sjögren M, Blomberg M, Johnson M, Wahlund LO, Edman Å, Lind K, Rosengren L, Blennow K, Wallin A. Neurofilament protein in cerebrospinal fluid – a marker of white matter changes. J Neurosci Res 2001;66:510-516.

 

Prince JA, Feuk L, Gottfries J, Ricksten A, Nägga K, Bogdanovic N, Blennow K, Brookes AJ. Lack of replication of association findings in complex disease: analysis of 15 polymorphisms in prior candidates for sporadic Alzheimer’s disease. Eur J Human Genet 2001;9:437-444.

 

Regland B, Lehmann W, Abedini I, Blennow K, Jonsson M, Karlsson I, Sjögren M, Wallin A, Xilinas M, Gottfries CG. Treatment of Alzheimer’s disease with clioquinole. Dement Geriatr Cogn disord 2001;12:408-414.

 

Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K. Transient increase in CSF total tau but not phospho-tau after acute stroke. Neurosci Lett 2001;297:187-190.

 

Tarkowski E, Liljeroth AM, Nilsson Å, Minthon L, Blennow K. Decreased levels of intrathecal IL-1 receptor antagonist in Alzheimer’s disease. Dementia Ger Cogn Disord 2001;12:314-317.

 

Prince JA, Feuk L, Howell WM, Jobs M, Emahazion T, Blennow K, Brookes AJ. Robust and accurate single nucleotide polymorphism genotyping by dynamic allele specific hybridization (DASH): design criteria and assay validation. Genome Research 2001;11:152-162.

 

Sjögren M, Davidsson P, Gottfreis J, Vanderstichele H, Edman Å, Vanmechelen E, Wallin A, Blennow K. The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer’s disease, reflecting a common pathophysiological process. Dement Geriatr Cogn Disord 2001;12:257-264.

 

Davidsson P, Paulsson L, Hesse C, Blennow K, Nilsson C. Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. Proteomics 2001;1:444-452.

 

Sjögren M, Hesse C, Basun H, Köl G, Thostrup H, Kilander L, Marcusson J, Edman Å, Wallin A, Karlsson I, Troell M, Wachmeister G, Ekdahl A, Olofsson H, Sandström A, Andreasen N, Minthon L, Blennow K. Tacrine and rate of progression in Alzheimer’s disease: relation to the ApoE allele genotype. J Neural Transm 2001;108:451-458.

 

Hesse C, Nilsson C, Blennow K, Davidsson P. Identification of the apolipoprotein E4 isoform in cerebrospinal fluid with preparative two-dimensional electrophoresis and matrix asisted laser desorption/ionizatoin-time of flight-mass spectrometry. Electrophoresis 2001;22:1834-1837.

 

Froelich Fabre S, Forsell C, Viitanen M, Sjögren M, Wallin A, Blennow K, Blomberg M, Andersen C, Wahlund L-O, Lannfelt L. Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E epsilon 4 frequency, but No Tau Gene Mutations. Exp Neurol 2001;168:413-418.

 

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K. Evaluation of CSF-tau and CSF-Ab42 as diagnostic markers for Alzheimer’s disease in clinical practice. Arch Neurol 2001;58:373-379.

 

Eriksson M, Berggren U, Blennow K, Fahlke C, Balldin J. Further investigation of citalopram on alcohol consumption in heavy drinkers: responsiveness possibly linked to the DRD2 A2/A2 genotype. Alcohol 2001;24:15-23.

 

Andreasen N, Gottfries J, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Rosengren L, Blennow K. Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and b-amyloid metabolism in Alzheimer’s disease. J Neurol Neurosurg Psychaitry 2001;71:557-558.

 

Söderström H, Blennow K, Manhem A, Forsman A. CSF studies in violent offenders I: 5-HIAA as a negative and HVA as a positive predictor of psychopathy. J Neural Transm 2001;108:869-878.

 

Robertsson B, Blennow K, Bråne G, Edman Å, Karlsson I, Wallin A, Gottfries CG. Hyperactivity in the hypothalamic-pituitary-adrenal axis in patients with delirium. Int Clin Psychopharmacol 2001;16:39-47.

 

Gottfries J, Blennow K, Lehmann MW, Regland B, Gottfries CG. One-carbon metabolism and other biochemical correlates of cognitive impairment as visualized by principal component analysis. J Geriatr Psychiatry Neurol 2001;14:109-114.

 

Söderström H, Blennow K, Manhem A, Forsman A. CSF studies in violent offenders II: blood-brain barrier dysfunction without concurrent inflammation or structyre degeneration. J Neural Transm 2001;108:879-886.

 

Nilsson C, Westman A, Minthon L, Blennow K, Ekman R. Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer’s disease and frontotemporal dementia. Peptides. 2001;22:2105-12.

 

Lidström AM, Hesse C, Rosengren L, Davidsson P, Blennow K. Normal levels of clusterin in cerebrospinal fluid in Alzheimer’s disease, and no change after acute ischemic stroke. J Alzhemier Disease 2001;3:435-442.

 

Davidsson P, Bogdanovic, N, Lannfelt L, Blennow K. Reduced expression of amyloid precursor protein, presenilin 1, and rab3a in cortical brain regions in Alzheimer’s disease. Dement Geriatr Cogn Disord 2001;12:243-250.

 

Sjögren M, Davidsson P, Tullberg M, Minthon L, Wallin A, Wikkeslö C, Granerus AK, Vanderstichele H, Vanmechelen E, Blennow K. Both total and hyperphosphorylated tau are increased in Alzehimer’s disease. J Neurol Neurosurg Psychiatry 2001;70:624-630.

 

Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A. Local and systemic GM-CSF increase in Alzheimer’s disease and vascular dementia. Acta Neurol Scand 2001;103:166-174.

 

Sjögren M, Vanderstichele H, Ågren H, Zachrisson O, Edsbagge M, Wikkelsö C, Skoog I, Wallin A, Wahlund LO, Marcusson J, Nägga K, Andreasen N, Davidsson P, Vanmechelen E, Blennow K. Tau and Ab42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001;47:1776-1781.

 

Chamoun V, Zeman A, Blennow K, Fredman P, Wallin A, Keir G, Giovannoni G, Thompson EJ. Haptoglobins as markers of blood-CSF barrier dysfunction: the findings in normal CSF. J Neurol Sci 2001;182:117-121.

 

Bjarnadottir M, Nilsson C, Lindström V, Westman A, Davidsson P, Thormodsson F, Blöndal H, Gudmundsson G and Grubb A. The cerebral hemorrhage-producing cystatin C variant (L68Q) in extracellular fluids. Amyloid, 8(1), (2001) 1

 

Ekman R, Gobom J, Persson R, Mecocci P, Nilsson CL. Arginine vasopressin in the cytoplasm and nuclear fraction of lymphocytes from healthy donors and patients with depression or schizofrenia. Peptides. 2001 Jan; 22(1):67-72.

 

Nilsson T, Zetterberg H, Wang YC, Rymo L. Promoter-proximal regulatory elements involved in oriP-EBNA1-independent and -dependent activation of the Epstein-Barr virus C promoter in B-lymphoid cell lines. J Virol. 2001;75:5796-811.


2000

 

Grundström E, Lindholm D, Johansson A, Blennow K, Askmark H. GDNF but not BNDF is increased in cerebrospinal fluid in amyotrophic lateral sclerosis. Neuroreport 2000;11:1781-1783.

 

Blennow K, Ricksten A Prince JA, Brookes AJ, Emahazion T, Wasslavik C, Bogdanovic N, Andreasen N, Båtsman S, Marcusson J, Nägga K, Wallin A, Regland B, Olofsson H, Hesse C, Davidsson P, Minthon L, Jansson A, Palmqvist L, Rymo L. No association between the a2-macroglobulin (A2M) deletion and Alzheimer’s disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm 2000;107:1065-1079.

Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minhon L, Wallin A, Blennow K, Vanmechelen E. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-258.

 

Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van der Perre B, Sjögren M, Andreasen N, Blennow K. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.

 

Eriksson M, Berggren U, Blennow K, Fahlke C, Månsson JE, Balldin J. Alcoholics with the DRD2 A1 have lower platelet MAO-B activity than those with the A2 allele: a preliminary study. Alcohol and Alcoholism 2000;35:493-498.

 

Sjögren M, Rosengren L Minthon L, Davidsson P, Blennow K Wallin A. Cytoskeleton proteins in CSF distinguish frontotemporal dementia from Alzheimer’s disease. Neurology 2000;54:1960-1964.

 

Tullberg M, Månsson JE, Fredman P, Lekamn A, Blennow K, Ekman R, Rosengren L, Tisell M, Wikkelsö C. CSF sulfatide distinguishes between normal pressure hydrocephalus and subcortical arteriosclerotic encephalopathy. J Neurol Neurosurg Psychiatry 2000;69:74-81.

 

Tarkowski E, Rindkvist Å, Blennow K, Wallin A, Wennmalm Å. Intrathecal release of nitric oxide in Alzheimer’s disease and vascular dementia. Dement Geriatr cogn disord 2000;11:322-326.

 

Tarkowski E, Liljeroth AM, Nilsson Å, Ricksten A, Davidsson P, Minthon L, Blennow K. TNF gene polymorphism and its relation to intracerebral production of TNFa and TNFb in AD. Neurology 2000;54:2077-2081.

 

Wallin A, Sjögren M, Edman Å, Blennow K, Regland B. Symptoms, vascular risk factors and blood-brain barrier dysfunction in relation to CT white-matter changes in dementia. Eur Neurol 2000;44:229-235.

 

Sjögren M, Minthon L, Davidsson P, Granérus AK, Clarberg A, Vanderstichele H, Vanmechelen E, Wallin A, Blennow K. CSF levels of tau, b-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm 2000;107:563-579.

 

Prince JA, Harro J, Blennow K, Gottfries CG, Oreland L. Putamen mitochondrial energy metabolism is highly correlated to emotional and intellectual impairment in schziophrenics. Neuropsychopharmacology 2000;22:284-292.

 

Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C, Davidsson P, Blennow K. Cerebrospinal fluid markers for Alzheimer’s disease evaluated after acute ischemic stroke. J Alzheimer Disease 2000;2:199-206.

 

Zachrisson OCG, Balldin J, Ekman R, Naesh O, Rosengren L, Ågren H, Blennow K. No evident neuronal damage after electroconvulsive therapy. Psychiatry Res 2000;96:157-165.

 

Blennow K, Bogdanovic N, Heilig M, Grenfeldt B, Karlsson I, Davidsson P. Reduction of the synaptic protein rab3a in the thalamus and connecting brain regions in post-mortem schizophrenic brains. J Neural Transm 2000;107:1085-1097.

 

Hesse C, Larsson H, Fredman P, Minthon L, Andreasen N, Davidsson P, Blennow K. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 2000;25:511-517.

 

Bogdanovic N, Davidsson P, Volkmann I, Winblad B, Blennow K. Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer’s disease: a quantitative and immunohistochemical study. J Neural Transm 2000;107:463-478.

 

Bergquist J, Andersen O and Westman A. A rapid method to characterize mutations transthyretin in cerebrospinal fluid from familial amyloidotic polyneuropathy patients using matrix-assisted laser desorption/ionization mass spectrometry. Clinical Chemistry, 46 (2000) 1293

 

Gobom J, Kreauter KO, Persson R, Steen H, Roepstorff P, Ekman R. Detection and quantification of neurotensin in human brain tissue by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chem. 2000 Jul 15, 72(14):3320-6.

 

Sidansvarig: Staffan Persson|Sidan uppdaterades: 2010-06-02
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?